general Translated · English · 2–5m lag

The European Commission is currently receiving new treatment for broken pancreas cancer: patients live on average 12.4 months longer

The European Commission has approved Daraxonrasib twice a day, a new treatment for broken pancreas cancer.The authorisation was granted through an accelerated procedure because there are few other treatments available to this patient group.

Reported by Het Laatste Nieuws
Read the complete report at Het Laatste Nieuws ↗
Verification notice

IntelMap indexes open-source reporting. This page identifies what a source reported; it does not independently confirm the claim.

INCIDENT FUSION

2 reports · 2 sources

Het Laatste NieuwsThe European Commission is currently receiving new treatment for broken pancreas cancer: patients live on average 12.4 months longerHet Laatste NieuwsThe European Commission is currently receiving new treatment for broken pancreas cancer: patients live on average 12.4 months longer
INCIDENT EVOLUTION

9 recorded states

Signal first indexedP1 · 68% quality · 1 source

Corroboration 1→2 sources · quality 68→72P1 · 72% quality · 2 sources

Quality 72→76P1 · 76% quality · 2 sources

Quality 76→80P1 · 80% quality · 2 sources

Quality 80→84P1 · 84% quality · 2 sources

Quality 84→88P1 · 88% quality · 2 sources

Quality 88→92P1 · 92% quality · 2 sources

Quality 92→96P1 · 96% quality · 2 sources

Quality 96→99P1 · 99% quality · 2 sources

Explore this day in the archive →
QUALITY CONTROL

Report this signal

Reports are anonymous and retained privately for editorial review.